N-[3,4-dihydro-2(1H)-isoquinolinyl]-N-methyleneamine | 1160165-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四氢异喹啉
• 英文名称: N-[3,4-dihydro-2(1H)-isoquinolinyl]-N-methyleneamine
• 英文别名: N-methylene-3,4-dihydroisoquinolin-2(1H)-amine；N-(3,4-dihydro-1H-isoquinolin-2-yl)methanimine
• CAS: 1160165-45-6
• 化学式: C₁₀H₁₂N₂
• 分子量: 160.219
• InChiKey: TUGVQHITNKNJDS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  15.6
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-[3,4-dihydro-2(1H)-isoquinolinyl]-N-methyleneamine 、 1,2,3,4-四氢-2-亚硝基-异喹啉 以the title compound (2.86 g, yield 95%) was obtained as a pale-yellow oil的产率得到N-methyl-3,4-dihydroisoquinolin-2(1H)-amine
  参考文献：
  名称：

  Homocysteine synthase inhibitor

  摘要：

  本发明提供了一种对于预防或治疗涉及到同型半胱氨酸合酶的疾病有用的同型半胱氨酸合酶抑制剂。该同型半胱氨酸合酶抑制剂是式(I)的化合物，其中每个符号如本文所定义，或其药理学可接受的盐，或其溶剂化物。

  公开号：

  US08513235B2
• 作为产物：
  描述：

  N-Methyl-1,2-diaziridino-Py-tetrahydro-isochinolin 以 邻二甲苯 为溶剂， 反应 10.0h， 生成 N-[3,4-dihydro-2(1H)-isoquinolinyl]-N-methyleneamine
  参考文献：
  名称：

  Thermal opening of the diaziridine fragment in 1-methyl-and 1,3,3-trimethyl-1,3,4,8b-tetrahydro-[1,2]diazirino[3,1-a]isoquinolines in the presence of n-arylmaleimides

  摘要：

  The thermal opening of the diaziridine ring in 1-methyl- and 1,3,3-trimethyl-1,3,4,8b-tetra-hydro[1,2]diazirino[3,1-a]isoquinolines in the presence of N-arylmaleimides leads to the predominant or exclusive formation of the trans isomers of the products of 1,3-dipolar cycloaddition. In the absence of dipolarophile, the conversion of the starting diaziridines is incomplete over the same time period, while the thermolysis products are N-[3,4-dihydro-2(1H)-isoquinolyl]-and N-[3,3-dimethyl-3,4-di-hydro-2(1H)-isoquinolyl]-N-methyleneamines formed as the result of isomerization of intermediate labile azomethineimines.

  DOI：

  10.1007/s10593-008-0122-5

文献信息

• THERAPEUTIC AGENT FOR CEREBRAL INFARCTION
  申请人：Nakao Akira

  公开号：US20120196824A1

  公开（公告）日：2012-08-02

  The invention provides a therapeutic drug for ischemic stroke. The therapeutic drug has the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof, as an active ingredient.

  这项发明提供了一种用于缺血性中风的治疗药物。该治疗药物具有如下式（I）的化学式，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物，作为活性成分。
• HOMOCYSTEINE SYNTHASE INHIBITOR
  申请人：Nakao Akira

  公开号：US20110034440A1

  公开（公告）日：2011-02-10

  The invention provides a homocysteine synthase inhibitor useful for the prophylaxis or treatment of diseases involving homocysteine synthase. The homocysteine synthase inhibitor is a compound of the formula (I) wherein each symbol is as defined herein, or a pharmacologically acceptable salt thereof, or a solvate thereof.

  本发明提供了一种同型半胱氨酸合酶抑制剂，可用于预防或治疗涉及同型半胱氨酸合酶的疾病。该同型半胱氨酸合酶抑制剂是公式(I)的化合物，其中每个符号如本文所定义，或其药理学上可接受的盐，或其溶剂化物。
• COMPOUND INHIBITING BUTYRYLCHOLINESTERASE
  申请人：Julius-Maximilians-Universität Würzburg

  公开号：EP3683219A1

  公开（公告）日：2020-07-22

  The invention concerns a compound according to formula wherein 3 < n < 11, wherein R comprises or consists of a heterocycle comprising one tertiary amino group providing the binding of R to the rest of the molecule and at least three carbon atoms, wherein all carbon atoms of the heterocycle are unsubstituted.

  本发明涉及一种根据式 其中 3 < n < 11，R 包括或由杂环组成，杂环由一个提供 R 与分子其余部分结合的叔氨基和至少三个碳原子组成，其中杂环的所有碳原子均未被取代。
• US8513235B2
  申请人：——

  公开号：US8513235B2

  公开（公告）日：2013-08-20
• Thermal opening of the diaziridine fragment in 1-methyl-and 1,3,3-trimethyl-1,3,4,8b-tetrahydro-[1,2]diazirino[3,1-a]isoquinolines in the presence of n-arylmaleimides
  作者：Yu. B. Koptelov、S. P. Saik、A. P. Molchanov

  DOI：10.1007/s10593-008-0122-5

  日期：2008.7

  The thermal opening of the diaziridine ring in 1-methyl- and 1,3,3-trimethyl-1,3,4,8b-tetra-hydro[1,2]diazirino[3,1-a]isoquinolines in the presence of N-arylmaleimides leads to the predominant or exclusive formation of the trans isomers of the products of 1,3-dipolar cycloaddition. In the absence of dipolarophile, the conversion of the starting diaziridines is incomplete over the same time period, while the thermolysis products are N-[3,4-dihydro-2(1H)-isoquinolyl]-and N-[3,3-dimethyl-3,4-di-hydro-2(1H)-isoquinolyl]-N-methyleneamines formed as the result of isomerization of intermediate labile azomethineimines.